These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 11732405

  • 1. [PEG-interferon alfa 2a against hepatitis C. Better as the standard therapy].
    MMW Fortschr Med; 2001 Nov 01; 143(44):58. PubMed ID: 11732405
    [No Abstract] [Full Text] [Related]

  • 2. Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
    AIDS Treat News; 2002 Oct 18; (384):5. PubMed ID: 12434764
    [No Abstract] [Full Text] [Related]

  • 3. Persistence with hepatitis C therapy in the Department of Veterans Affairs.
    Iqbal SU, Cunningham F, Lee A, Miller DR, Li NC, Cheung R, Kazis L.
    J Clin Pharm Ther; 2008 Jun 18; 33(3):251-61. PubMed ID: 18452412
    [Abstract] [Full Text] [Related]

  • 4. Delaying HCV treatment in HIV-positive patients.
    Carter M.
    IAPAC Mon; 2005 May 18; 11(5):147. PubMed ID: 16201045
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of combined interferon and ribavirin for treatment of hepatitis C.
    Brown JL.
    Lancet; 1998 Jan 10; 351(9096):78-9. PubMed ID: 9439486
    [No Abstract] [Full Text] [Related]

  • 6. Second thoughts about secondary analyses.
    Ferenci P.
    Dig Liver Dis; 2005 Oct 10; 37(10):805-7; author reply 808-9. PubMed ID: 16023903
    [No Abstract] [Full Text] [Related]

  • 7. [Recurrence after customary hepatitis C therapy. Those patients are now treatable, too].
    MMW Fortschr Med; 2003 Feb 27; 145(9):55. PubMed ID: 12666534
    [No Abstract] [Full Text] [Related]

  • 8. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J, Sulkowski M.
    J Viral Hepat; 2008 Jul 27; 15(7):475-81. PubMed ID: 18363672
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
    Andriulli A, Mangia A.
    N Engl J Med; 2007 Oct 18; 357(16):1660; author reply 1661-2. PubMed ID: 17942881
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Fried MW, Hadziyannis SJ.
    Semin Liver Dis; 2004 Oct 18; 24 Suppl 2():47-54. PubMed ID: 15346246
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of acute hepatitis C].
    Grangé JD.
    Gastroenterol Clin Biol; 2002 Apr 18; 26 Spec No 2():B32-7. PubMed ID: 12180306
    [No Abstract] [Full Text] [Related]

  • 12. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
    Liu CH, Chen DS, Kao JH.
    N Engl J Med; 2007 Oct 18; 357(16):1661; author reply 1661-2. PubMed ID: 17948345
    [No Abstract] [Full Text] [Related]

  • 13. [Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
    MMW Fortschr Med; 2003 Jun 26; 145(26):52-3. PubMed ID: 12916339
    [No Abstract] [Full Text] [Related]

  • 14. Management of hepatitis C.
    Sjogren MH.
    Gastroenterology; 2006 Jul 26; 131(1):332; author reply 332-3. PubMed ID: 16831622
    [No Abstract] [Full Text] [Related]

  • 15. Pegylated interferon (PEG-Intron) for chronic hepatitis C.
    Med Lett Drugs Ther; 2001 Jun 25; 43(1107):54-5. PubMed ID: 11426190
    [No Abstract] [Full Text] [Related]

  • 16. Advances in the treatment of hepatitis C: combination antiviral therapy with interferon alfa-2b and ribavirin.
    Benson L, Birkel A, Caldwell L, Stafford-Fox V, Casarico B.
    J Am Acad Nurse Pract; 2000 Sep 25; 12(9):364-73. PubMed ID: 11930591
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis C in 2012.
    Lemon M.
    S D Med; 2012 Nov 25; 65(11):432-3. PubMed ID: 23189411
    [No Abstract] [Full Text] [Related]

  • 18. [Treatment of hepatitis C virus infection].
    Zeuzem S.
    Praxis (Bern 1994); 2005 May 04; 94(18):721-6. PubMed ID: 15938383
    [Abstract] [Full Text] [Related]

  • 19. [Recent trends in the therapy of hepatitis C].
    Meschini A, Lucchetta MC, Fontana M, Nocchi S, Pace A, Grassi M.
    Clin Ter; 2003 May 04; 154(3):181-91. PubMed ID: 12910808
    [Abstract] [Full Text] [Related]

  • 20. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire Int; 2003 Dec 04; 12(68):206-10. PubMed ID: 14986684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.